RXDX Ignyta Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Ignyta, Inc. to Roche Holding AG is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) stock prior to December 22, 2017.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ignyta, Inc. to Roche Holding AG for $27.00 in cash per share of Ignyta. To learn more about the action and your rights, go to:

http://www.zlk.com/mna/ignyta-inc

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of Ignyta breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Roche Holding AG is underpaying for Ignyta shares, thus unlawfully harming Ignyta shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
28/12/2017

Underlying

RXDXIgnyta Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ignyta Inc.

 PRESS RELEASE
Free
RXDX IGNYTA INC.

Ignyta to Present at 36th Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 9:00 a.m. Pacific time. The conference will be held at the Westin St. Francis Hotel in San Francisco. A webcast of the presentation will be available during the presentation in the Investors section of the company...

January 4, 2018 1 EN
 PRESS RELEASE
Free
RXDX IGNYTA INC.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Inves...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) stock prior to December 22, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ignyta, Inc. to Roche Holding AG for $27.00 in cash per share of Ignyta. To learn more about the action and your rights, go to: http://www.zlk.com/mna/igny...

January 3, 2018 1 EN
 PRESS RELEASE
Free
RXDX IGNYTA INC.

Ignyta Reports FDA Clearance of IND for RXDX-106, a Novel Immunomodula...

SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for RXDX-106, a novel oral immunomodulatory agent and TAM inhibitor, in patients with solid tumors. Under this IND, the company intends to initiate the TITAN (Targeted Immunomodulatory TAM ANtagonist) study, a first-in-human, open label, multicenter, dose escalation s...

December 29, 2017 1 EN
 PRESS RELEASE
Free
RXDX IGNYTA INC.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investi...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) stock prior to December 22, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ignyta, Inc. to Roche Holding AG for $27.00 in cash per share of Ignyta. To learn more about the action and your rights, go to: http://www.zlk.com/mna/igny...

December 28, 2017 1 EN
 PRESS RELEASE
Free
RXDX IGNYTA INC.

IGNYTA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Inves...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Ignyta, Inc. (NASDAQ CM: RXDX)? Did you purchase any of your shares prior to December 22, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Ignyta, Inc. (“Ignyta” or the “Company”) (NASDAQ CM: RXDX) regarding possible...

December 27, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch